Ofra Ziv-Polat

Ofra Ziv-Polat

Auto-generated profile, based on publicly available information

Ofra Ziv-Polat

NVR Research Ltd., Ness-Ziona, Israel

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2010 in Biomaterials
Verified
Journal Article
Closed access
OZOfra Ziv-Polat
Ofra Ziv-Polat
MTMoris Topaz
Moris Topaz
TBTamar Brosh
Tamar Brosh
SMShlomo Margel
Shlomo Margel

1 March 2012 in International Journal of Nanomedicine
Verified
Journal Article
Open access
OZOfra Ziv-Polat
Ofra Ziv-Polat
HSHadas Skaat
Hadas Skaat
ASAbraham Shahar
Abraham Shahar
SMShlomo Margel
Shlomo Margel
Peer reviewed article authored by (Ziv-Polat O, Skaat H, Shahar A, Margel S). Read article or submit your manuscript for publishing.

1 January 2014 in BioMed Research International
Verified
Journal Article
Open access
PDF file
OZOfra Ziv-Polat
Ofra Ziv-Polat
ASAbraham Shahar
Abraham Shahar
ILItay Levy
Itay Levy
HSHadas Skaat
Hadas Skaat
SNSara Neuman
Sara Neuman
SMShlomo Margel
Shlomo Margel
Local delivery of neurotrophic factors is a pillar of neural repair strategies in the peripheral nervous system. The main disadvantage of the free growth factors is their short half-life of few minutes. In order to prolong their activity, we have conjugated to iron oxide nanoparticles three neurotrophic factors: nerve growth factor (βNGF), glial cell-derived neurotrophic factor (GDNF), and basic fibroblast growth factor (FGF-2). Comparative stability studies of free versus conjugated factors revealed that the conjugated neurotrophic factors were significantly more stable in tissue cultures and in medium at 37°C. The biological effects of free versus conjugated neurotrophic factors were examined on organotypic dorsal root ganglion (DRG) cultures performed in NVR-Gel, composed mainly of hyaluronic acid and laminin. Results revealed that the conjugated neurotrophic factors enhanced early nerve fiber sprouting compared to the corresponding free factors. The most meaningful result was that conjugated-GDNF, accelerated the onset and progression of myelin significantly earlier than the free GDNF and the other free and conjugated factors. This is probably due to the beneficial and long-acting effect that the stabilized conjugated-GDNF had on neurons and Schwann cells. These conclusive results make NVR-Gel enriched with conjugated-GDNF, a desirable scaffold for the reconstruction of severed peripheral nerve.

7 May 2015 in Journal of Nanobiotechnology
Verified
Journal Article
Open access
PDF file
ILItay Levy
Itay Levy
ISIfat Sher
Ifat Sher
ECEnav Corem-Salkmon
Enav Corem-Salkmon
OZOfra Ziv-Polat
Ofra Ziv-Polat
AMAmilia Meir
Amilia Meir
YRYgal Rotenstreich
Ygal Rotenstreich
Iron oxide (IO) nanoparticles (NPs) of sizes less than 50 nm are considered to be non-toxic, biodegradable and superparamagnetic. We have previously described the generation of IO NPs coated with Human Serum Albumin (HSA). HSA coating onto the IO NPs enables conjugation of the IO/HSA NPs to various biomolecules including proteins. Here we describe the preparation and characterization of narrow size distribution core-shell NIR fluorescent IO/HSA magnetic NPs conjugated covalently to Fibroblast Growth Factor 2 (FGF2) for biomedical applications. We examined the biological activity of the conjugated FGF2 on human bone marrow mesenchymal stem cells (hBM-MSCs). These multipotent cells can differentiate into bone, cartilage, hepatic, endothelial and neuronal cells and are being studied in clinical trials for treatment of various diseases. FGF2 enhances the proliferation of hBM-MSCs and promotes their differentiation toward neuronal, adipogenic and osteogenic lineages in vitro. The NPs were characterized by transmission electron microscopy, dynamic light scattering, ultraviolet–visible spectroscopy and fluorescence spectroscopy. Covalent conjugation of the FGF2 to the IO/HSA NPs significantly stabilized this growth factor against various enzymes and inhibitors existing in serum and in tissue cultures. IO/HSA NPs conjugated to FGF2 were internalized into hBM-MSCs via endocytosis as confirmed by flow cytometry analysis and Prussian Blue staining. Conjugated FGF2 enhanced the proliferation and clonal expansion capacity of hBM-MSCs, as well as their adipogenic and osteogenic differentiation to a higher extent compared with the free growth factor. Free and conjugated FGF2 promoted the expression of neuronal marker Microtubule-Associated Protein 2 (MAP2) to a similar extent, but conjugated FGF2 was more effective than free FGF2 in promoting the expression of astrocyte marker Glial Fibrillary Acidic Protein (GFAP) in these cells. These results indicate that stabilization of FGF2 by conjugating the IO/HSA NPs can enhance the biological efficacy of FGF2 and its ability to promote hBM-MSC cell proliferation and trilineage differentiation. This new system may benefit future therapeutic use of hBM-MSCs.

13 February 2012 in Advanced Healthcare Materials
Verified
Journal Article
Closed access
PDF file
HSHadas Skaat
Hadas Skaat
OZOfra Ziv‐Polat
Ofra Ziv‐Polat
ASAbraham Shahar
Abraham Shahar
DLDavid Last
David Last
YMYael Mardor
Yael Mardor
SMShlomo Margel
Shlomo Margel

1 October 2011 in European Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
DMDana M. Mizrahi
Dana M. Mizrahi
OZOfra Ziv-Polat
Ofra Ziv-Polat
BPBenny Perlstein
Benny Perlstein
EGEran Gluz
Eran Gluz
SMShlomo Margel
Shlomo Margel